Core Insights - CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics aimed at treating genetic diseases by restoring healthy protein levels [1][3] - The company has granted a non-qualified stock option for 80,000 shares to a new employee as an inducement for joining the company [1][2] Stock Option Details - The stock option has a ten-year term with an exercise price of $4.39, equal to the closing price on the grant date [2] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on continued service [2] Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases, utilizing a proprietary RAP Platform to amplify mRNA and target regulatory RNAs [3] - The therapeutic approach focuses on amplifying healthy protein expression, which may provide significant clinical benefits for conditions characterized by haploinsufficiency and recessive partial loss-of-function disorders [3]